Navkiranjot Brar, MD
Nephrology · Shelby Township, MINPI 1235351263
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $147 of the $202 with a category attached, or 72.6%. Bard Peripheral Vascular, Inc. accounts for 72.6% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2024 at $164 and has fallen 88.5% since, to $19 in 2025. That places this record below the midpoint for nephrology clinicians in MI, where the typical reported total is $606.
Across 5 payments — averaging $40.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$147
- Aurinia Pharma U.S., Inc.$20
- Boehringer Ingelheim$19
- Travere Therapeutics, Inc.$17
Across 74 payments — averaging $3186.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$223K
- Akebia Therapeutics Inc$13K
What the payments were for
- Food & beverage$14773%
- Education$5527%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bard Peripheral Vascular, Inc. | 2 | $147 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Travere Therapeutics, Inc. | 1 | $17 |
How this compares
$202 in reported general payments places this provider in the 25th percentile of 325 nephrology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 11 | $18,192 |
| Sevelamer Carbonate | 76 | $16,255 |
| Lanthanum Carbonate | 13 | $15,627 |
| Potassium Citrate ErPotassium Citrate | 34 | $6,853 |
| Calcium Acetate | 47 | $6,319 |
| Eplerenone | 16 | $3,323 |
| Carvedilol | 101 | $1,264 |
| Torsemide | 67 | $1,153 |
| Losartan Potassium | 77 | $770 |
| Chlorthalidone | 61 | $767 |
| Metoprolol Succinate | 25 | $673 |
| Hydralazine Hcl | 24 | $614 |
| Gentamicin Sulfate | 12 | $595 |
| Spironolactone | 43 | $529 |
| Nifedipine ErNifedipine | 17 | $513 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Shelby Township
- Alexander YevzlinAnn Arbor$1.1M
- Muwaffaq SalamehBay City$164K
- Laura MarianiAnn Arbor$150K
- Crystal Gardner-MartinLivonia$140K
- Katherine KwonSaint Joseph$111K
- Anatole BesarabDetroit$102K
- Richard CrossSaint Clair Shores$96K
- Kausik UmanathDetroit$85K
- Joel TopfRoseville$79K
- Matthias KretzlerAnn Arbor$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.